News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Shareholders Complain and Vent About Stock Losses at Annual Meeting



6/14/2012 6:50:11 AM

Dendreon shareholders strafed the Seattle biotechnology company's leadership with criticism at Wednesday's annual meeting, upset at the stock's 82 percent decline in the past year. But new CEO John Johnson seemed unruffled by the barrage, and may have scored some points with investors by hinting that Dendreon may find a marketing partner for its Provenge cancer therapy in Europe, rather than going it alone. "You all ought to be fired for cause," longtime stockholder and Seattle resident Charles Heffernan told the management team when he got the microphone.

Read at Seattle Times
Read at Xconomy
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES